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OBJECTIVE—People with type 1 diabetes have increased risk of hospital admission compared
with those without diabetes. We hypothesized that HbA1c would be an important indicator of
risk of hospital admission.
RESEARCH DESIGN AND METHODS—The Scottish Care Information–Diabetes
Collaboration, a dynamic national register of diagnosed cases of diabetes in Scotland, was linked
to national data on admissions. We identiﬁed 24,750 people with type 1 diabetes during January
2005 to December 2007. We assessed the relationship between deciles of mean HbA1c and
hospital admissions in people with type 1 diabetes adjusting for patient characteristics.
RESULTS—Therewere 3,229 hospital admissions. Of the admissions, 8.1%of people hadmean
HbA1c,7.0% (53 mmol/mol) and 16.3% had HbA1c,7.5% (58 mmol/mol). The lowest odds of
admissionwere associatedwithHbA1c7.7–8.7%(61–72mmol/mol).Whencomparedwith this decile, a
J-shaped relationship existed between HbA1c and admission. The highest HbA1c decile (10.8–18.4%/
95–178mmol/mol) showed signiﬁcantly higher odds ratio (95%CI) for any admission (2.80, 2.51–
3.12); the lowest HbA1c decile (4.4–7.1%/25–54 mmol/mol) showed an increase in odds of
admission of 1.29 (1.10–1.51). The highest HbA1c decile experienced signiﬁcantly higher odds
of diabetes-related (3.31, 2.94–3.72) and diabetes ketoacidosis admissions (10.18, 7.96–13.01).
CONCLUSIONS—People with type 1 diabetes with highest and lowest mean HbA1c values
were associatedwith increased odds of admission. People with highHbA1c (.10.8%/95mmol/mol)
were at particularly high risk. There is the need to develop effective interventions to reduce this risk.
Diabetes Care 34:1992–1997, 2011
People with type 1 diabetes are at in-creased risk of hospital admissioncompared with the general popula-
tion (1–3). A previous study in Tayside,
Scotland found that 25% of people with
type 1 diabetes had had at least one hos-
pital admission in 1995, 2.89-fold higher
than the general population (2). Hospital
admissions are key drivers of the in-
creased costs of diabetes born by health
care systems as well as reﬂecting prevent-
able morbidity suffered by patients.
HbA1c has a central clinical role in
counseling patients regarding risks of hy-
poglycemia, vascular, and other complica-
tions of diabetes (4). National guidelines
promote targets for glycemic control based
on HbA1c and attempt to minimize both
risk of complications as well as risk of hy-
poglycemia (5).
We hypothesized that HbA1c would
be an important indicator of risk of hos-
pital admission and might be useful in
deﬁning that part of the population likely
to suffer morbidity and incur an increase
in hospital costs in the short and medium
term. Such information could inform de-
sign of interventional programs promot-
ing reduction in morbidity and costs of
diabetes; prioritizing health policies; and
identifying which subgroup of patients,
determined by HbA1c, would beneﬁt most.
We examined the association be-
tween HbA1c levels and risk of hospital
admission in the Scottish type 1 diabetic
population.
RESEARCH DESIGN AND
METHODS
Datasets
The Scottish Care Information–Diabetes
Collaboration (SCI-DC) is a dynamic na-
tional register of diagnosed cases of diabe-
tes in Scotland (www.diabetesinscotland.
org.uk). SCI-DC contains records for over
99% of diagnosed cases of diabetes (6) with
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detailed clinical information including
BMI, creatinine, age, sex, and HbA1c.
Type 1 diabetes was identiﬁed using an al-
gorithm that incorporated age, drug pre-
scription, and clinical description of the
type of diabetes. Cross referencing of dia-
betes coded in routinehospital discharge in-
formation (SMR01) found that a diagnosis
of diabetes was present in Scottish Mor-
bidity Records (SMR01) in people absent
from the SCI-DC register in 0.6% of cases
(H. Anwar, personal communication).
Information on hospital admissions
was obtained using SMR01, national data
on hospital admissions from Information
Services Division (ISD) of NHS National
Services, Scotland. The SMR01 records
contain over 95% of Scotland’s hospital
admissions and include administrative
data and demographic information such
as age, sex, and postcode of the patient.
Details of individual episodes of care are
recorded within each admission with up
to six International Classiﬁcation of Dis-
eases (ICD-10) diagnosis codes and up to
four procedure codes per episode.
Data were linked within the NHS
using a unique patient identiﬁer, the Com-
munityHealth Index (CHI) number, where
available. Where CHI was not available
linkage was obtained using probabilistic
methods based on name, sex, date of birth,
and postcode, as previously described (7).
No personal identiﬁers were released to re-
searchers, and all subsequent analyses were
conducted on anonymized datasets.
Individuals were excluded from the
analysis where there were inconsistencies
in date of birth or sex between SCI-DC
and SMR01 (379 patients), no date of
diagnosis (103 patients), or no clinical
and no hospital admission data existing
for the years 2005–2007 (345 patients).
All patients with type 1 diabetes register
with a general practitioner to obtain sup-
plies of insulin. Thus the population in-
cludes people with type 1 diabetes who
attend specialist clinics, their general prac-
titioner for routine care, and those who
may not attend for regular follow-up but
have had a measurement of HbA1c during
the study period. HbA1c was measured
using a variety of clinical methods, all of
which were Diabetes Control and Com-
plications Trial (DCCT) aligned. In this
retrospective cohort study, we identiﬁed
24,750 people with type 1 diabetes dur-
ing January 2005 to December 2007.
Outcomes
The primary outcome of the study was
any admission to hospital, with secondary
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analysis of subgroups of ICD-10 codes
for hospital admissions. Secondary analysis
admissions were deﬁned as a composite
of all admissions because of diabetes or di-
abetes complications (excluding vascular
disease), hypoglycemia, diabetes with ke-
toacidosis (DKA; without coma), vascular
causes, and cancer. The ICD-10 codes for
each type of outcome are listed in the Sup-
plementary Data. Where coma is present
(“Diabetes mellitus with coma”: E 16.0),
coding does not allow differentiation be-
tween comawith associated hypoglycemia,
ketoacidosis, or hyperglycemia. Therefore,
this coding was not included in either the
hypoglycemic or hyperglycemic groups
but was considered a composite group of
hypoglycemia, diabetic ketoacidosis, and
diabetes with coma under the heading
“dysglycemia.”
For the purposes of this analysis the
vascular and cancer admissions were
coded using the principal diagnostic po-
sition of the ﬁrst episode, and diabetes-
related admissions, hypoglycemia, DKA,
and dysglycemia were identiﬁed using
any diagnostic position.
Statistical methods
Of all the variables, only 4% of datapoints
were missing. Imputation of missing data
(mean HbA1c, BMI, and serum creatinine)
was performed using standard regression
techniques. Deciles of mean levels of all
HbA1c measurements over the study pe-
riod were estimated. Individual patient
HbA1c was summarized as the mean of
all observations per year and assigned a
decile. Association between deciles of
HbA1c and all-cause admission was as-
sessed using logistic regression models
clustered by person. Parametric rela-
tionships between continuous variables
and outcomes were examined using the
grouped smoothing and fractional poly-
nomial methods (8). Only linear relation-
ships were included in ﬁnal models since
higher order relationships did not im-
prove model ﬁt. The referent decile was
chosen to be the decile that provided the
lowest odds of admission in univariate
analyses (decile 3, mean HbA1c 7.9, range
7.7–8.1%). Outcomes were expressed as
odds ratio (OR) of admission with corre-
sponding 95% CIs for each decile com-
pared with the reference category. Models
were adjusted for potential confounding
factors including age, sex, presence of
previous vascular disease (ICD-9: 410–
414, 430–438, 443; ICD-10: I20–25,
I60–69, I73), mean serum creatinine,
mean BMI, and diabetes duration at hos-
pital admission. Sensitivity analysis was
performed by excluding measurements
taken within 6 months of diagnosis, those
patients with suspected renal failure, and
patients under 18 years of age. Annual
number of days in hospital for those who
were admitted was calculated by taking the
median of the total days in hospital divided
by the length of time exposed to diabetes
over the study period.
RESULTS
Patient characteristics
Baseline mean HbA1c for all people with
type 1 diabetes was 8.9% (SD 1.5). On
average, there were 8.6 HbA1c measure-
ments per person during the study period
(SD 5.7). Female sex, younger age, and
shorter duration of diabetes were associ-
ated with higher HbA1c (Table 1).
HbA1c and hospital admission
Over the 3 years, 49% of people with type
1 diabetes were admitted at least once
accounting for 33,516 hospital admis-
sions (2.8 hospital admissions per person
on average if admitted at least once). The
number of admissions was markedly
higher in the highest HbA1c decile
(10.8–18.4%) with 5,481 admissions in
the 3-year period compared with 2,566
in the reference decile (decile 3, HbA1c
7.7–8.1%). Despite younger age and
shorter duration of diabetes, decile 10 ac-
counted for 16% of all admissions and
deciles 8–10 accounted for 38% of admis-
sions. The proportion of admissions be-
cause of cancer (5.8%) decreased with
HbA1c decile (11.8% in lowest, 1.2% in
highest decile). The proportion of admis-
sions as a result of ketoacidosis (14.4%)
increased with HbA1c decile (3.7% in
lowest, 33.1% in highest decile), as did
the proportion of dysglycemia admissions
(7.0% in lowest, 36.6% in highest decile).
The number of admissions for diabetes
Table 2—Unadjusted and adjusted analysis of HbA1c and all-cause admission to hospital
Unadjusted Adjusted†
OR (95% CI) SE OR (95% CI) SE
Male 0.867 (0.812–0.926) 0.029 0.746 (0.697–0.798) 0.026
Age (years)* 1.007 (1.005–1.009) 0.001 1.002 (1.000–1.005) 0.001
Previous vascular admission 3.772 (3.392–4.194) 0.204 3.111 (2.782–3.479) 0.177
Creatinine (mmol/L)*† 1.009 (1.008–1.010) 0.000 1.009 (1.008–1.010) 0.000
BMI (kg/m2)*† 0.996 (0.991–1.002) 0.003 0.989 (0.983–0.995) 0.003
Diabetes duration (years)* 1.005 (1.003–1.008) 0.001 0.989 (0.986–0.992) 0.002
HbA1c (mean of decile values)‡
Decile 1 (mean 6.5) 1.382 (1.219–1.567) 0.089 1.306 (1.145–1.489) 0.088
Decile 2 (mean 7.4) 1.183 (1.048–1.336) 0.073 1.149 (1.022–1.291) 0.068
Decile 3 (mean 7.8) Reference Reference Reference Reference
Decile 4 (mean 8.2) 1.382 (0.965–1.328) 0.096 1.401 (1.218–1.611) 0.099
Decile 5 (mean 8.5) 1.438 (1.295–1.596) 0.077 1.423 (1.289–1.567) 0.076
Decile 6 (mean 8.9) 1.622 (1.452–1.812) 0.092 1.664 (1.489–1.861) 0.095
Decile 7 (mean 9.2) 2.074 (1.862–2.310) 0.114 2.116 (1.904–2.351) 0.114
Decile 8 (mean 9.7) 1.514 (1.358–1.688) 0.084 1.506 (1.350–1.679) 0.084
Decile 9 (mean 10.4) 1.801 (1.613–2.011) 0.101 1.836 (1.644–2.050) 0.103
Decile 10 (mean 12.0) 2.796 (2.505–3.120) 0.156 2.905 (2.599–3.247) 0.165
*Per 1 unit increase; †mean of any values recorded between January 2005/date of diagnosis andDecember 2007/date of death; ‡multivariate analysis results for model
including all factors in table.
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with coma (E10.0) was quite low: 287
compared with 6,422 under the general
dysglycemia heading.
Odds of admission increased with
higher serum creatinine, age, female sex,
previous vascular admission, and lower
BMI (Table 2). In univariate analysis there
was a J-shaped relationship of HbA1c with
an increased likelihood of admission in
the lowest decile and signiﬁcantly higher
(and increasing) likelihood of admission
in deciles 5 through 10. The relationship
ofHbA1c to admission did not substantially
change after inclusion of sex, age, previous
vascular admission, and BMI in a multivar-
iate model (Table 2), where likelihood of
hospital admissionwas greatest in decile 10
(adjusted OR 2.80 [95% CI 2.51–3.12]).
However, the lowest decile was also asso-
ciated with higher odds of all-cause admis-
sion (1.38 [1.22–1.57]). The increased
odds of admission in the lowest decile per-
sisted even after exclusion of admissions
as a result of hypoglycemia and cancer
(Fig. 1A) and all diabetes-related admis-
sions (Fig. 1B).
Within the subgroup of causes of ad-
mission, there was an inverse relationship
between HbA1c and likelihood of cancer
(Table 3) and positive relationships be-
tween HbA1c and likelihood of ketoaci-
dotic, vascular, and all other diabetes
admissions. The relationship of HbA1c to
all diabetes-related admissions was partic-
ularly strong with almost a fourfold in-
crease in likelihood of admission in the
highest decile compared with the referent
decile.
CONCLUSIONS—People with type 1
diabetes experience a large number of
hospital admissions. In 1995, people with
type 1 diabetes in the Tayside region of
Scotland had an ;25% chance of hospi-
talization and the 864 people in the study
accounted for some 2,261 days in hospi-
tal (2). Since that time the estimated prev-
alence of type 1 diabetes has increased from
0.24% of the Scottish population to 0.4%,
an increase that reﬂects increasing inci-
dence and possibly improved survival (9)
but alsomore complete ascertainment. Data
are now available for the entire Scottish
population. Each year, people with type 1
diabetes in Scotland had an;24% chance
of hospitalization and the 24,750 people in
the study accounted for 71,330 days in
hospital, with an annual median of 2 days
in the hospital for those admitted, a ﬁgure
comparable with previous data (2).
We investigated risk factors for ad-
mission and in particular HbA1c. Our
analysis shows that low (4.4–7.1%/25–
54 mmol/mol) and high (10.8–18.4%/
95–178 mmol/mol) mean HbA1c values
were associated with increased odds of
admission compared with HbA1c levels of
between 7.7 and 8.1% (61–65mmol/mol).
This J-shaped relationship does not ap-
pear to be accounted for by hospitaliza-
tion around the time of diagnosis since
the relationship between HbA1c and all-
cause admission is maintained even after
excluding those patients who had diabetes
for less than 180 days, and excluding mea-
surements taken within the ﬁrst 6 months
of diagnosis and those under the age of
18 years (data not shown). A recent study
has shown a similar J-shaped relationship
between HbA1c and mortality (10) in pa-
tients with type 2 diabetes.
We observe higher odds of hospital-
ization for those in the lowest decile of
HbA1c. Although lower HbA1c is associated
Figure 1—Adjusted OR (and 95% CI) of types of admission to hospital (reference decile = 3) by
HbA1c decile: all-cause excluding hypoglycemia and cancer (A) and all-cause excluding diabetes
related (B). Dashed vertical lines represent the HbA1c range of each decile. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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with an increase in risk of hypoglycemia
(4) this does not obviously account for
the increase in admissions we observe
since there is no increase in hypoglycemic
admissions. Clearly most hypoglycemic
episodes will not result in hospital admis-
sion. We cannot exclude some failure to
detect admissions complicated by hypo-
glycemia because of failure to code for
this at hospital discharge. A further poten-
tial explanation would be reverse causality
with HbA1c falling in response to major
illness, although given the observational
nature of the dataset we cannot exclude
other possibilities.
For deciles 6–10 (8.7–18.4%/72–178
mmol/mol), the likelihood of admission
increases markedly with HbA1c and the
highest levels mark out a group with
high odds of admission and potential as-
sociated hospital costs. Decile 10 experi-
ence 16% of all hospital admissions and
19% of all diabetes-related admissions de-
spite being younger. There is an increase in
diabetes-related and vascular admissions in
the highest HbA1c decile compared with
the reference group. For diabetes-related
admissions this increase persists even after
exclusion of admissions in the ﬁrst 6
months after diagnosis. For cancer admis-
sions, there was a slight decrease in odds of
admission as HbA1c increased. However,
because of the wide CIs, there was a lack
of signiﬁcance in most deciles. More de-
tailed analysis of cancer admission and
mortality will be of interest.
One of the aims of this study was to
determine whether HbA1c could identify
a group with high rates of admission that
might be amenable to programs supporting
patients and reducing admission. Some ad-
missions may represent the longer term ef-
fects of higher blood glucose leading to
complications (4,11) and would require
long-term improvements in glycemic con-
trol to reduce the likelihood of admission.
Nevertheless, it is notable that HbA1c above
8.4% (68 mmol/mol) is associated with
increased risk of hospital admission and
particularly high levels of admission in
the highest HbA1c decile. Raised HbA1c
identiﬁes a vulnerable part of the diabetic
population at high risk of hospital admis-
sion resulting in substantial health care
costs, a group for whom interventions
might usefully be targeted. When com-
paring HbA1c decile 10 to the reference
decile there were an extra 2,915 hospital
admissions over the 3-year period, the great
majority of which were in our diabetes-
related group (2,759), the majority of these
with dysglycemia coded as a cause of
admission (1,658), and the great majority
of those coded under diabetic ketoacidosis
(1,616). Given an average cost of admis-
sions in people with diabetes of around
£2,424 (12), this crudely suggests an extra
cost for those with HbA1c .10.8% of up
to £2.4m per annum for all admissions,
£1.3m per annum for admissions compli-
cated by ketoacidosis, and £4m per annum
for the dysglycemia outcome. Although it
is acknowledged that not all of these ad-
missions may be prevented, programs di-
rected to prevention of hospital admissions
would appear to have extensive scope to be
cost effective.
One of the striking features of this
dataset is the overall level of HbA1c ach-
ieved in our population. National clinical
guidance in 2001 suggested an aim of an
HbA1c below 7% in keeping with other
national and international bodies. Notably,
only 8% of our population in 2005–2007
were achievingHbA1c,7% (53mmol/mol)
and only 16% with mean HbA1c under
7.5% (58 mmol/mol). This is higher than
national ﬁgures for adolescents (11–14
years of age) in our population (9.7%below
7.5% with mean HbA1c 9.2%). Other con-
temporary series have shown similar results
(proportion,7% in Australia 13%) (13).
We take advantage of linked data for
both hospital admissions (SMR01) and
clinical information (SCI-DC). These data
provide almost 100% coverage for people
with type 1 diabetes in Scotland during
2005–2007, avoiding problems of under-
reporting of diabetes in hospital discharge
information or selected patient groups in
previous studies. Some limitations are
identiﬁed. First, we used an algorithm to
determine type of diabetes. As with nearly
every other cohort study of this scale and
type, there is a potential for misclassiﬁ-
cation of diabetes type. However, it is be-
lieved that this will be an extremely small
percentage. Second, we have used the an-
nual average level of HbA1c. This was cho-
sen as the best measure of prevailing
HbA1c for each person. It does not cap-
ture variability of HbA1c, which would
merit further examination. For some out-
comes (for example hyper- and hypoglyce-
mic admissions) HbA1c before admission
could be argued to be more appropriate.
These types of admissions were also ana-
lyzed using last available HbA1c, and inter-
estingly this made no difference to the
conclusions (data not shown). Third, only
those admitted into hospitals were included
as admitted. Often, glycemic patients are
treated in accident and emergency or
as an outpatient, neither of which wereT
ab
le
3—
A
dj
us
te
d
an
al
ys
is
(O
R
an
d
95
%
C
I)
of
H
bA
1
c
an
d
ad
m
is
si
on
to
ho
sp
it
al
fo
r
va
ri
ou
s
re
co
rd
ed
di
ag
no
se
s
D
ec
ile
D
ia
be
te
s
re
la
te
d
*
H
yp
og
ly
ce
m
ia
D
K
A
C
om
a,
D
K
A
,o
r
hy
p
og
ly
ce
m
ia
†
C
an
ce
r
V
as
cu
la
r
1
1.
07
3
(0
.9
48
–
1.
21
5)
0.
66
1
(0
.4
63
–
0.
94
4)
0.
68
7
(0
.5
05
–
0.
93
4)
0.
73
5
(0
.5
78
–
0.
93
5)
2.
31
1
(1
.2
03
–
4.
43
8)
1.
05
9
(0
.6
71
–
1.
67
0)
2
1.
08
0
(0
.9
46
–
1.
23
2)
0.
91
1
(0
.6
55
–
1.
26
7)
0.
88
2
(0
.6
38
–
1.
21
9)
0.
96
6
(0
.7
59
–
1.
23
0)
1.
64
9
(0
.9
64
–
2.
82
2)
0.
85
3
(0
.5
28
–
1.
37
6)
3
R
ef
er
en
ce
R
ef
er
en
ce
R
ef
er
en
ce
R
ef
er
en
ce
R
ef
er
en
ce
R
ef
er
en
ce
4
1.
29
6
(1
.1
26
–
1.
49
2)
0.
97
7
(0
.7
00
–
1.
36
4)
1.
46
3
(1
.1
00
–
1.
94
4)
1.
28
0
(1
.0
25
–
1.
59
8)
3.
70
4
(1
.8
35
–
7.
48
0)
1.
12
7
(0
.7
04
–
1.
80
5)
5
1.
43
2
(1
.1
27
–
1.
60
4)
1.
20
4
(0
.8
81
–
1.
64
6)
2.
14
8
(1
.6
49
–
2.
79
7)
1.
75
4
(1
.4
20
–
2.
16
7)
2.
50
8
(1
.4
07
–
4.
47
0)
1.
64
0
(1
.0
80
–
2.
48
9)
6
1.
69
5
(1
.5
06
–
1.
90
9)
1.
24
3
(0
.9
01
–
1.
71
4)
3.
26
0
(2
.5
14
–
4.
22
7)
2.
41
6
(1
.9
55
–
2.
98
5)
1.
34
3
(0
.7
18
–
2.
51
4)
1.
41
6
(0
.8
83
–
2.
26
9)
7
2.
25
9
(2
.0
20
–
2.
52
6)
1.
78
8
(1
.3
16
–
2.
42
9)
3.
82
1
(2
.9
81
–
4.
89
7)
2.
99
4
(2
.4
51
–
3.
65
8)
1.
47
0
(0
.7
99
–
2.
70
7)
1.
84
3
(1
.2
06
–
2.
81
9)
8
1.
57
1
(1
.3
98
–
1.
76
7)
1.
12
9
(0
.8
11
–
1.
57
1)
3.
32
2
(2
.5
59
–
4.
31
3)
2.
34
0
(1
.8
86
–
2.
90
4)
1.
09
0
(0
.5
60
–
2.
12
1)
1.
62
6
(1
.0
41
–
2.
53
9)
9
1.
93
8
(1
.7
17
–
2.
18
7)
1.
12
7
(0
.8
10
–
1.
57
0)
4.
81
9
(3
.6
98
–
6.
28
1)
3.
15
0
(2
.5
35
–
3.
91
4)
1.
37
3
(0
.7
10
–
2.
65
6)
1.
67
7
(1
.0
52
–
2.
67
3)
10
3.
30
7
(2
.9
35
–
3.
72
5)
1.
43
6
(1
.0
44
–
1.
97
3)
10
.1
81
(7
.9
64
–
13
.0
15
)
6.
29
9
(5
.1
45
–
7.
71
2)
0.
58
2
(0
.2
96
–
1.
14
3)
1.
74
9
(1
.0
73
–
2.
85
0)
*I
n
cl
ud
es
ke
to
ac
id
os
is
an
d
hy
po
gl
yc
em
ia
;†
D
K
A
.
1996 DIABETES CARE, VOLUME 34, SEPTEMBER 2011 care.diabetesjournals.org
HbA1c and hospital admission in type 1 diabetes
accounted for in this analysis. Finally, in de-
termining the reason for admission we rely
on hospital admission data to detect each
type of admission. These data are depen-
dent on the accuracy of ICD coding, which
is around 90% in general (see http://www.
isdscotland.org/isd/2737.html). More de-
tailed conﬁrmation of the codes related to
diabetes, particularly the group of codes
around admission for hypoglycemia and
ketoacidosis, is necessary to conﬁrm the
nature of admissions. Further work is also
required to determine whether these ad-
missions could be prevented.
Our data suggest HbA1c is an effective
way of identifying patients at higher risk
of hospital admission. Targeting these
patients may be an effective strategy for
lowering risk of admission and health
care costs. Higher levels of HbA1c is a
strong predictor of hospital admissions,
suggesting that effective interventions to
lower HbA1c in this group could result in
considerably lower hospital admissions
and associated costs for the care of people
with type 1 diabetes.
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